Company > Strategy

Acacia Pharma aims to become a leading hospital pharmaceuticals business selling products directly to anesthesiologists and oncologists in the US. The key elements of this strategy are:

  • Directly commercialize Barhemsys® and Byfavo® in the US through our own sales and marketing infrastructure.
  • Establish strategic partnerships for the commercialization of Barhemsys® and APD403 outside the US with companies that have local expertise and commercial infrastructure, initially focusing on the major pharmaceutical markets.
  • Leverage our US commercial infrastructure to sell APD403 for CINV to oncologists.
  • Consider the further in-licensing or acquisition of complementary products or product candidates that can be commercialized effectively through our US organization.